Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January – March 2020

Significant events during the first quarter 2020 · The company commissioned the grid owner to move a 50kV line · Bergsstaten approved the company’s application for an exploration permit for an area next to the existing mining concessions in Blötberget First quarter, 1 January – 31 March 2020 · Income amounted to SEK 0 million (0) · Earnings after tax amounted to SEK -2.5 million (-2.5) · Investments during the period January – March totalled SEK 0.4 million (5.4) · Basic earnings per share were SEK -0.08 (-0.12) · Cash as per 31 March 2020 amounted to 7.5 million (

ExpreS2ion – Interim report for the first quarter 2020 published

Hørsholm, Denmark, May 20, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's interim report for the first quarter 2020 is published. The interim report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “Our decision to develop a COVID-19 vaccine is a great, albeit highly accelerated, example of Expres[2]ion’s new strategy. It will not always be this fast, but we believe we are now prepared in ExpreS[2]ion to develop our own pipeline.” First quarter (01/

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previously received approval by the Russian Ethics Committee. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include about 100 patients and will be conducted at about 20 clinical sites in the Netherlands,

Kavli chooses Rejlers as its total provider of IT services

Kavli has chosen Rejlers as its total provider of IT services. The agreement covers a wide range of IT services for the entire Kavli Group and makes Rejlers an important partner in the process of realising Kavli's Industry 4.0 ambitions.The agreement means that Rejlers delivers most of the company's IT services related to operations, storage and monitoring, including the infrastructure that powers Kavli's mission-critical business systems, as well as a number of other critical applications. Kavli's brands are well known and can be found on dining tables in many countries around the world.

SRV Group Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act

SRV GROUP PLC   STOCK EXCHANGE RELEASE     20 MAY 2020 AT 09.20 EET SRV Group Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act SRV Group Plc has received an announcement from Timo Kokkila on 19 May 2020, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement Timo Kokkila’s indirect holding through Havu Capital Oy, a company controlled by him, in SRV Group Plc has on 19 May 2020 decreased below 10 per cent of the total shares and votes in SRV Group Plc as a result of SRV Group Plc's

Finnair adjusts volume-driven costs in line with demand and additionally targets almost 80-million-euro permanent cost base decline from 2022 onwards

Finnair Plc         Stock Exchange Release           20 May 2020 at 9.16 a.m. EEST Finnair adjusts its volume-driven costs in line with demand. Due to for example the Finnish temporary layoff practices, a significant part of Finnair’s costs can be adjusted in accordance with demand in the prevailing market conditions. In 2019, volume-driven costs formed c. 60% of Finnair’s total cost base. In addition, Finnair targets almost 80-million-euro permanent cost base decline starting from year 2022 compared to year 2019. Finnair seeks savings in for example real estate costs, aircraft

Qlife Holding AB, Interim Report January – March 2020

Expansion with molecular test on the Egoo systemFINANCIAL SUMMARY FIRST QUARTER 2020 · Revenue for the period amounted to kSEK 385 (0) and regards a collaboration project with a Danish hospital. · EBITDA for the period amounted to kSEK -5,732 (-1,875), and net profit amounted to kSEK -8,704 (-1,893). · Qlife issued 4,472,600 units (4,472,600 shares and 4,472,600 warrants series TO1) through a new share issue in February 2020. Equity capital increased with kSEK 48,950 after issuance costs of kSEK 6,063, and net cash flow from the IPO amounted to kSEK 44,450 after netting of loans

Finnair plans to adjust personnel resources to the decreased operations due to coronavirus situation

Finnair begins discussions with its employees on possible additional layoffs. Between April and June From July, Finnair flies only 5 per cent of its normal traffic and has thus already temporarily laid off its personnel. Finnair will gradually add frequencies and routes back to its network starting from July. In July, Finnair aims to operate approximately 30% of its normal amount of flights. Finnair will review its schedule on a monthly basis and will update it as travel restrictions are removed and demand starts to recover. It estimates to fly approximately 70 percent of its normal

SRV Group Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act

SRV GROUP PLC   STOCK EXCHANGE RELEASE     20 MAY 2020 AT 09.15 EET SRV Group Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act SRV Group Plc has received an announcement from Ilpo Kokkila on 19 May 2020, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement Ilpo Kokkila’s indirect holding through AS Pontos Baltic and Kolpi Investments Oy, companies controlled by him, in SRV Group Plc ‘s shares increased above 25 per cent of the total shares and votes in SRV Group Plc as a result of

Varner chooses Nepa for their brand tracking program

STOCKHOLM, Sweden (May 20th, 2020) - Nepa, a leading Consumer Research and analytics company, providing insight solutions to drive brand and sales by increasing marketing effectiveness, has been chosen by Varner to implement and run a brand tracking program to help Varner understand how its own brands perform on their main markets.  “The brand tracking service provided by Nepa has enabled us to monitor brand performance on a chain- and group level. This enables us to identify growth potential for individual chains and for the group, as well as learning more about how individual brand

American Shipping Company ASA - First quarter 2020 financial results

Lysaker, 20 May 2020, American Shipping Company ASA (“AMSC” or the “Company”) announces results for first quarter ending 31 March 2020. HIGHLIGHTS · AMSC successfully closed a USD 305 million bank debt refinancing with new and existing lenders at attractive and improved terms. The new debt facilities reduce cost of capital and increase free cash flow · Stable Q1 financial performance with bareboat revenue of USD 21.9 million, normalized EBITDA of USD 22.0 million and adjusted net profit of USD 2.9 million · Backlog of secured bareboat revenue of USD 300.4 million with average

Invitation to analyst presentation Q1 Report 2020

Following the announcement of Cabonline Group Holding AB (publ) (the "Company") interim report for January - March 2020, the company invites analysts to a video conference on Friday, May 29, 2020, at. 14 pm.Cabonline CEO Peter Viinapuu will present the Company’s interim report for the period January - March 2020. Following the presentation, the CEO and the CFO Anneli Lindblom are available for questions. The interim report will be published on Friday, May 29, 2020. Further, it is noted that Pareto Security AS will continue to co-ordinate and support the Company in respect of its senior

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

20 May 2020 07:00 BST Lynparza approved in the US for HRR gene-mutatedmetastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival vs. enzalutamide or abiraterone in a biomarker-based subset of prostate cancer patients  with BRCA1/2 or ATM mutations Approximately 20-30% of men with metastatic castration-resistant prostate cancer have an HRR gene mutation AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for

Eurobattery Minerals AB hereby publishes its Interim Report January – March 2020

First quarter 2020 (same period previous year) · Net sales amounted to SEK 0 (SEK 0). · Operating income after depreciation/amortisation and financial items totalled KSEK -2,248 (KSEK -2,104) · Earnings per share after depreciation/amortisation and financial items amounted to SEK -0.23 (SEK -0.08). · Cash flow from operating activities was KSEK -1,564 (KSEK -1,564). Significant events during the period · The Company received the final assay results during the reporting period following completion of a 4 hole, 998m drill programme in the fourth quarter of 2019 at

Notice of the Annual General Meeting for Gränges AB

The Gränges AB Board of Directors has resolved to convene an annual general meeting of shareholders to be held Thursday, 25 June 2020. More detailed information about the contents of the proposals may be obtained from the complete notice to the annual general meeting below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar) and on the company’s website within the next few days. English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take

Faron Pharmaceuticals Oy Harmful association of glucocorticoids in interferon beta-1a treated patients published in Intensive Care Medicine

· Detailed analyses following INTEREST trial conclude glucocorticoids block the upregulation of CD73 in the lung capillaries and inhibit interferon signallingTURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the results of its detailed analyses into the effects of glucocorticoids on intravenous (IV) interferon (IFN) beta-1a activity, which arose following the INTEREST trial in 2018, have been published in Intensive Care Medicine, a world leading journal in the field of critical care. The results

Notice of the Annual General Meeting of SinterCast AB (publ)

The shareholders of SinterCast AB (publ), reg. no. 556233-6494 (“SinterCast”) are hereby invited to participate in the Annual General Meeting to be held on Tuesday 23 June 2020, 15:00 hours, at the premises of the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden. Information Related to COVID-19 In consideration of COVID-19 concerns, SinterCast encourages shareholders to not attend the Annual General Meeting. Instead, shareholders are encouraged to vote by post. Information regarding voting by post and a template for voting by post will be made

IMPROVED EARNINGS AND CONTINUED GROWTH

This is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs.   FIRST QUARTER, JANUARY – MARCH 2020 ·Net sales increased by 4.7%, or 3.8% FX adjusted, to MSEK 69.4 (66.3) · Gross profit increased by 2.7%, or 1.6% FX adjusted, to MSEK 52.2 (50.9) · EBIT was MSEK -0.3 (-3.3) · Earnings after tax was MSEK 0.4 (-3.6) · Earnings per share was, basic SEK 0.06 (-0.49), diluted SEK 0.06 (-0.49)  IMPORTANT EVENTS   DURING THE PERIOD        ·P-O Westerlund was appointed as new CEO on January

OrtoWay creates new segment in spinal field with next-generation hydraulically powered OrtoWell® Distractor.

OrtoWay AB, makers of the OrtoWell® Distractor – the world’s first hydraulically powered device for spinal surgery – today announces new tool design improvements extending the clinical usage. It has also formed a new subsidiary and established manufacturing in Tuttlingen, Germany to secure world-class quality – laying a safe and solid foundation for US launch.For the first time ever, the novel device puts hydraulic power in the hands of spinal surgeons for safer, smoother, gentler and more controlled separation of vertebral bodies – ensuring high accuracy in fixation. Compared with manual

Scout Gaming publishes Q1 2020: Revenues increased 149% to mSEK 8.7

”We started the year at a high pace and maintained good momentum from the fourth quarter last year. Revenues increased by 149% to SEK 8.7 million, while all profit measures compared to corresponding quarter previous year continued to improve. In mid-March, however, like many parts of the world, we experienced an abrupt halt because of the global outbreak of COVID-19.  Since we control the entire production chain ourselves, from the technical platform, statistics, pricing to graphic design, we have succeeded in providing a competitive product even though the sports calendar has appeared

Hansa Biopharma announces upcoming presentations including a late breaking poster presentation at the 2020 American Transplant Congress

Abstract highlights · 2-year follow-up data demonstrates graft survival of 90% for 31 patients post imlifidase treatment with a median eGFR of 61.5 ml/min. Despite varying levels of DSA rebound among these imlifidase-desensitized patients, the AMR frequency was comparable with those reported in other studies with less sensitized patients.  · Reallocation of kidneys due to positive crossmatch affects the refused organ by increasing cold ischemia time and the eventual discard of kidneys. · Anti-HLA IgM antibodies are unaffected by imlifidase treatment.Lund May 20, 2020. Hansa

Changes in Gjensidige's Group Management

Gjensidige Forsikring ASA will make changes in its Group Management effective from 1 June 2020. René Fløystøl, who is in charge of E-commerce and digital channels in the Private segment, will assume the position as Executive Vice President for Private. He will replace Sigurd Austin who left the company in April this year. Tor Erik Silset will be the new EVP for Technology and Infrastructure. He will replace Kaare Østgaard, who moves to the new position as Project director with responsibility for the company’s group projects. Tor Erik Silset comes from the position as leader of

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Tuesday June 23, 2020 at 15:00 CEST at the Elite Hotel Ideon, Scheelevägen 27, SE-223 63 Lund, Sweden. Registration will begin at 14:00 CEST and will end when the meeting starts.Lund May 20, 2020. Information in relation to the Corona virus (COVID-19) In view of the recent developments of the spread of the Corona virus (COVID-19), Hansa Biopharma has taken certain precautionary measures in relation to the Annual General Meeting on June 23, 2020. The measures are being

There are no items matching the current filter
There are no more items matching the current filter
Back to top